Sjögren syndrome

CMAJ

Volumn 186, Issue 15, 2014, Pages E579-E586

  Mavragani, Clio P ^a   Moutsopoulos, Haralampos M ^b  

^a Departments of Physiology   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CEVIMELINE; CYCLOPHOSPHAMIDE; EYE DROPS; HYDROXYCHLOROQUINE; LA ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; RHEUMATOID FACTOR; RITUXIMAB; RO ANTIBODY; SALIVA SUBSTITUTE;

ARTHRALGIA; ARTHRITIS; BLOOD CELL COUNT; BONE MARROW BIOPSY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS VASCULITIS; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG RESPONSE; DRY EYE; DRY SKIN; ENDOSCOPY; EYE EXAMINATION; GLOMERULONEPHRITIS; HUMAN; IMMUNOASSAY; MOUTH HYGIENE; MYALGIA; PHYSICAL EXAMINATION; PREVALENCE; PROTEIN ELECTROPHORESIS; REVIEW; RHEUMATOID ARTHRITIS; SALIVARY GLAND BIOPSY; SALIVARY GLAND DISEASE; SCHIRMER TEST; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; THORAX RADIOGRAPHY; VAGINAL DRYNESS; VASCULITIS; XEROSTOMIA; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; RISK FACTOR; SJOGREN'S SYNDROME;

DIAGNOSIS, DIFFERENTIAL; HUMANS; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84908433293     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.122037     Document Type: Review

References (82)

1. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren's syndrome. Autoimmun Rev 2010;9:A305-10.
2. Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjögren's syndrome. Eur J Clin Invest 2010;40: 1026-36.
3. Yoshimi R, Ueda A, Ozato K, et al. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012; 2012: 606195.
4. Drosos AA, Andonopoulos AP, Costopoulos JS, et al. Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol 1988;27:123-7.
5. Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjögren's syndrome in two age-different communitybased populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol 2008;37:30-4.
6. Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012;91:1-9.
7. Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
8. Malladi AS, Sack KE, Shiboski S, et al. Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. Arthritis Care Res (Hoboken). 2012; 64:911-8.
9. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002; 46:741-7.
10. Sumida T, Tsuboi H, Iizuka M, et al. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. Mod Rheumatol 2013;23:841-5.
11. Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al. Obstetric and gynaecological profile in patients with primary Sjögren's syndrome. Ann Rheum Dis 1994;53:569-73.
12. Skopouli FN, Talal A, Galanopoulou V, et al. Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol 1990; 17: 618-20.
13. Ng WF, Bowman SJ. Primary Sjögren's syndrome: too dry and too tired. Rheumatology (Oxford) 2010;49:844-53.
14. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol 1994;33:745-8.
15. Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 2000;79:241-9.
16. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjögren's syndrome: an overview. J Autoimmun 2012;39:354-8.
17. Mavragani CP, Schini M, Gravani F, et al. Brief report: adrenal autoimmunity in primary Sjögren's syndrome. Arthritis Rheum 2012; 64:4066-71.
18. Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. Antiovarian antibodies in primary Sjögren's syndrome. Rheumatol Int 2007; 27: 1149-55.
19. Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. Am J Clin Pathol 1987;88:26-31.
20. Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004; 83: 96-106.
21. Brito-Zerón P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2013;31:103-10.
22. Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry 2011;82:798-802.
23. Alexander EL, Arnett FC, Provost TT, et al. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983;98:155-9.
24. Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjögren's syndrome. Ann Rheum Dis 2004; 63:616-20.
25. Tsampoulas CG, Skopouli FN, Sartoris DJ, et al. Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. Scand J Rheumatol 1986;15:333-9.
26. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004; 164: 1275-84.
27. Youinou P, Pennec YL, Katsikis P, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Br J Rheumatol 1990;29:205-7.
28. García-Carrasco M, Siso A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002; 29:726-30.
29. Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999;58:61-4.
30. Papiris SA, Tsonis IA, Moutsopoulos HM. Sjögren's syndrome. Semin Respir Crit Care Med 2007;28:459-71.
31. Hatzis GS, Fragoulis GE, Karatzaferis A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren's syndrome. J Rheumatol 2008;35:2012-6.
32. Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009;4:1423-31.
33. Moutsopoulos HM, Cledes J, Skopouli FN, et al. Nephrocalcinosis in Sjögren's syndrome: a late sequela of renal tubular acidosis. J Intern Med 1991;230:187-91.
34. Goules AV, Tatouli IP, Moutsopoulos HM, et al. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013;65:2945-53.
35. Caramaschi P, Biasi D, Caimmi C, et al. The co-occurrence of Hashimoto thyroiditis in primary Sjögren's syndrome defines a subset of patients with milder clinical phenotype. Rheumatol Int 2013;33:1271-5.
36. Moutsopoulos HM, Balow JE, Lawley TJ, et al. Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978; 64: 955-60.
37. Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993;19:869-908.
38. Wandinger KP, Stangel M, Witte T, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 2010;62:1198-200.
39. Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93.
40. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70:1363-8.
41. Hackett KL, Newton JL, Frith J, et al. Impaired functional status in primary Sjögren's syndrome. Arthritis Care Res (Hoboken) 2012; 64:1760-4.
42. Karaiskos D, Mavragani CP, Sinno MH, et al. Psychopathological and personality features in primary Sjögren's syndrome-associations with autoantibodies to neuropeptides. Rheumatology (Oxford) 2010;49:1762-9.
43. Drosos AA, Angelopoulos NV, Liakos A, et al. Personality structure disturbances and psychiatric manifestations in primary Sjögren's syndrome. J Autoimmun 1989;2:489-93.
44. Strömbeck B, Theander E, Jacobsson LT. Assessment of fatigue in primary Sjögren's syndrome: the Swedish version of the Profile of Fatigue. Scand J Rheumatol 2005;34:455-9.
45. Theander L, Strömbeck B, Mandl T, et al. Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? Rheumatology (Oxford) 2010;49:1177-83.
46. Gudbjörnsson B, Broman JE, Hetta J, et al. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32:1072-6.
47. Karaiskos D, Mavragani CP, Makaroni S, et al. Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis 2009;68:40-6.
48. Wöhrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia 2007;21:1812-8.
49. Nocturne G, Pavy S, Lazure T, et al. IgG4 multiorgan lymphoproliferative syndrome as a differential diagnosis of primary Sjögren's syndrome in men? Ann Rheum Dis 2011;70:2234-5.
50. Mavragani CP, Skopouli FN, Moutsopoulos HM. Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome. J Rheumatol 2009;36:1626-30.
51. Mavragani CP, Fragoulis GE, Rontogianni D, et al. Elevated IgG serum levels among primary Sjögren's syndrome patients: Do they unmask underlying IgG4-Related disease? Arthritis Care Res. 2013 DOI: 10.1002/acr.22216.
52. Liew MS, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol 2012;96:1498-503.
53. Dafni UG, Tzioufas AG, Staikos P, et al. Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis 1997; 56: 521-5.
54. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994;53: 637-47.
55. Stewart CM, Bhattacharyya I, Berg K, et al. Labial salivary gland biopsies in Sjögren's syndrome: still the gold standard? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106: 392-402.
56. Venables PJ, Shattles W, Pease CT, et al. Anti-La (SS-B): A diagnostic criterion for Sjögren's syndrome? Clin Exp Rheumatol 1989;7:181-4.
57. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
58. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87.
59. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren's syndrome. Clin Rev Allergy Immunol 2007;32:284-91.
60. Alves MB, Motta AC, Messina WC, et al. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a singleblind trial. Quintessence Int 2004;35:392-6.
61. Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86: 181-4.
62. Condon PI, McEwen CG, Wright M, et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol 1999;83:1121-4.
63. McDonald CC, Kaye SB, Figueiredo FC, et al. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) 2002;16:601-7.
64. Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome. Cornea 1996;15:120-8.
65. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9.
66. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304: 452-60.
67. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999;106:811-6.
68. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol 1990;108:577-83.
69. Vivino FB, Minerva P, Huang CH, et al. Corneal melt as the initial presentation of primary Sjögren's syndrome. J Rheumatol 2001;28:379-82.
70. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7.
71. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
72. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2006;2:252-61.
73. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012;8:399-411.
74. Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996;5(Suppl 1):S31-6.
75. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72:1026-31.
76. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996;14:555-8.
77. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
78. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007; 56: 3995-4004.
79. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
80. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71:84-7.
81. Mariette X, Gottenberg JE. Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010; 22: 471-7.
82. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7.